| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2012 | Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial | CHIH-HSIN YANG ; JIN-YUAN SHIH ; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; CHONG-JEN YU ; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; PAN-CHYR YANG ; Miller V.A. | The Lancet Oncology | 381 | 336 | |
| 2021 | Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis | Tan D.S.W.; Geater S.; CHONG-JEN YU ; Tsai C.-M.; Hsia T.-C.; Chen J.; Lin M.-C.; Lu Y.; Sriuranpong V.; Yang C.-T.; Sen P.; Branle F.; Shi M.; Wu Y.-L. | JTO Clinical and Research Reports | 3 | 0 | |
| 2011 | Different efficacies of erlotinib and gefitinib in Taiwanese patients with advanced non-small cell lung cancer: A retrospective multicenter study | Fan W.-C.; CHONG-JEN YU ; Tsai C.-M.; Huang M.-S.; Lai C.-L.; Hsia T.-C.; Tien Y.-J.; Huang S.-F.; Wu C.-H.; Chou K.-T.; Lee Y.-C.; Perng R.-P.; Chen Y.-M. | Journal of Thoracic Oncology | 24 | 21 | |
| 2021 | Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study | CHIH-HSIN YANG ; Reckamp K.L.; Kim Y.-C.; Novello S.; Smit E.F.; Lee J.-S.; Su W.-C.; Akerley W.L.; Blakely C.M.; Groen H.J.M.; Bazhenova L.; Carcereny Costa E.; Chiari R.; Hsia T.-C.; Golsorkhi T.; Despain D.; Shih D.; Popat S.; Wakelee H. | JTO Clinical and Research Reports | 9 | 0 | |
| 2022 | Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial | Lu S.; Wang Q.; Zhang G.; Dong X.; Yang C.-T.; Song Y.; Chang G.-C.; Lu Y.; Pan H.; Chiu C.-H.; Wang Z.; Feng J.; Zhou J.; Xu X.; Guo R.; Chen J.; Yang H.; Chen Y.; Yu Z.; Shiah H.-S.; Wang C.-C.; Yang N.; Fang J.; Wang P.; Wang K.; Hu Y.; He J.; Wang Z.; Shi J.; Chen S.; Wu Q.; Sun C.; Li C.; Wei H.; Cheng Y.; Su W.-C.; Hsia T.-C.; Cui J.; Sun Y.; Ou S.-H.I.; Zhu V.W.; CHIH-HSIN YANG | Journal of Thoracic Oncology | 51 | 45 | |
| 2015 | EGFR mutation and lobar location of lung adenocarcinoma | Tseng C.-H.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; CHAO-CHI HO ; Hsia T.-C.; KANG-YI SU ; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; KUAN-YU CHEN ; WEI-YU LIAO ; JIN-YUAN SHIH ; SUNG-LIANG YU ; CHONG-JEN YU ; PAN-CHYR YANG ; Yang T.-Y.; Chang G.-C. | Carcinogenesis | 10 | 11 | |
| 2015 | Epidermal growth factor receptor tyrosine Kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations | Chiu C.-H.; Yang C.-T.; JIN-YUAN SHIH ; Huang M.-S.; Su W.-C.; Lai R.-S.; Wang C.-C.; Hsiao S.-H.; Lin Y.-C.; Ho C.-L.; Hsia T.-C.; Wu M.-F.; Lai C.-L.; Lee K.-Y.; Lin C.-B.; Yu-Wung Yeh D.; Chuang C.-Y.; Chang F.-K.; Tsai C.-M.; Perng R.-P.; Chih-Hsin CHIH-HSIN YANG | Journal of Thoracic Oncology | 189 | 165 | |
| 2007 | Erratum: Urinary biomarker of oxidative stress correlating with outcome in critically septic patients (Intensive Care Medicine (2007) DOI: 10.1007/s00134-007-0715-y) | Cheng W.-E.; Shih C.-M.; Hang L.-W.; KUEN-YUH WU ; Yang H.-L.; Hsu W.-H.; Hsia T.-C. | Intensive Care Medicine | 1 | 1 | |
| 2019 | Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study | Wei Y.-F.; Huang W.-T.; Liu T.-C.; Shieh J.-M.; Chian C.-F.; Wu M.-F.; Chang C.-C.; Lin C.-H.; JEN-CHUNG KO ; Lin C.-M.; Hsia T.-C. | Journal of Cancer | 7 | 5 | |
| 2008 | High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy | Perng R.-P.; CHIH-HSIN YANG ; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; CHONG-JEN YU ; Chang W.-C.; Kuo H.-P.; Yu C.-T.; ZHONG-ZHE LIN ; Kao W.-Y. | Lung Cancer | 28 | 26 | |
| 2016 | Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients | Hsu K.-H.; Tseng J.-S.; Wang C.-L.; Yang T.-Y.; Tseng C.-H.; Chen H.-Y.; Chen K.-C.; Tsai C.-R.; Yang C.-T.; SUNG-LIANG YU ; KANG-YI SU ; CHONG-JEN YU ; CHAO-CHI HO ; Hsia T.-C.; Wu M.-F.; Chiu K.-L.; Liu C.-M.; PAN-CHYR YANG ; Chen J.J.W.; Chang G.-C. | Oncotarget | 9 | 8 | |
| 2015 | Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan | Hsu K.-H.; CHAO-CHI HO ; Hsia T.-C.; Tseng J.-S.; KANG-YI SU ; Wu M.-F.; Chiu K.-L.; Yang T.-Y.; Chen K.-C.; Ooi H.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; KUAN-YU CHEN ; WEI-YU LIAO ; JIN-YUAN SHIH ; SUNG-LIANG YU ; CHONG-JEN YU ; PAN-CHYR YANG ; Chang G.-C. | PLoS ONE | 93 | 86 | |
| 2021 | Lung Cancer in Republic of China | Luo Y.-H.; Chiu C.-H.; Scott Kuo C.-H.; Chou T.-Y.; Yeh Y.-C.; Hsu H.-S.; Yen S.-H.; Wu Y.-H.; CHIH-HSIN YANG ; BIN-CHI LIAO ; Hsia T.-C.; Chen Y.-M. | Journal of Thoracic Oncology | 22 | 17 | |
| 2020 | Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan | Chen Y.-M.; CHIH-HSIN YANG ; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; CHAO-CHI HO ; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; CHONG-JEN YU | Journal of the Formosan Medical Association | 7 | 4 | |
| 2022 | An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study | Su P.-L.; Chang G.-C.; Hsiao S.-H.; Hsia T.-C.; Lin M.-C.; Lin M.-H.; JIN-YUAN SHIH ; Yang C.-T.; Yang S.-H.; Chen Y.-M. | JTO Clinical and Research Reports | 2 | 0 | |
| 2003 | Prediction of Survival in Surgical Unresectable Lung Cancer by Artificial Neural Networks Including Genetic Polymorphisms and Clinical Parameters | Hsia T.-C.; Chiang H.-C.; Chiang D.; Hang L.-W.; Tsai F.-J.; Chen W.-C.; MING-HUANG CHIANG | Journal of Clinical Laboratory Analysis | 16 | 13 | |
| 2017 | Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer – A multicenter retrospective SEQUENCE study | Chang G.-C.; Tseng C.-H.; Hsu K.-H.; CHONG-JEN YU ; Yang C.-T.; Chen K.-C.; Yang T.-Y.; Tseng J.-S.; Liu C.-Y.; WEI-YU LIAO ; Hsia T.-C.; Tu C.-Y.; Lin M.-C.; Tsai Y.-H.; Hsieh M.-J.; Wu W.-S.; Chen Y.-M. | Lung Cancer | 22 | 19 | |
| 2019 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial | Nakagawa K.; Garon E.B.; Seto T.; Nishio M.; Ponce Aix S.; Paz-Ares L.; Chiu C.-H.; Park K.; Novello S.; Nadal E.; Imamura F.; Yoh K.; JIN-YUAN SHIH ; Au K.H.; Moro-Sibilot D.; Enatsu S.; Zimmermann A.; Frimodt-Moller B.; Visseren-Grul C.; Reck M.; Chu Q.; Cortot A.; Pujol J.-L.; Fabre E.; Lamour C.; Bischoff H.; Kollmeier J.; Kimmich M.; Engel-Riedel W.; Hammerschmidt S.; Schütte W.; Syrigos K.; Ho J.C.M.; Au K.-H.; Ardizzoni A.; Pasello G.; Gregorc V.; Del Conte A.; Galetta D.; Takahashi T.; Kumagai T.; Hotta K.; Goto Y.; Hosomi Y.; Sakai H.; Takiguchi Y.; Kim Y.H.; Kurata T.; Yamaguchi H.; Daga H.; Okamoto I.; Satouchi M.; Ikeda S.; Kasahara K.; Atagi S.; Azuma K.; Aoe K.; Horio Y.; Yamamoto N.; Tanaka H.; Watanabe S.; Nogami N.; Ozaki T.; Koyama R.; Hirashima T.; Kaneda H.; Tomii K.; Fujita Y.; Seike M.; Nishimura N.; Kato T.; Ichiki M.; Saka H.; Hirano K.; Nakahara Y.; Sugawara S.; Kim S.-W.; Min Y.J.; Lee H.W.; Kang J.-H.; An H.J.; Lee K.H.; Kim J.-S.; Lee G.-W.; Lee S.Y.; Alexandru A.; Udrea A.A.; Juan-Vidal Ó.; Nadal-Alforja E.; Gil-Bazo I.; Ponce-Aix S.; Rubio-Viqueira B.; Alonso Garcia M.; Felip Font E.; Fuentes Pradera J.; Coves Sarto J.; Lin M.-C.; Su W.-C.; Hsia T.-C.; Chang G.-C.; Wei Y.-F.; Su J.; Cicin I.; Goksel T.; Harputluoglu H.; Ozyilkan O.; Henning I.; Popat S.; Hatcher O.; Mileham K.; Acoba J.; Garon E.; Jung G.; Raj M.; Martin W.; Dakhil S. | The Lancet Oncology | 364 | 320 | |
| 2007 | Revisit of 1997 TNM staging system - Survival analysis of 1112 lung cancer patients in Taiwan | Perng R.-P.; Chen C.-Y.; Chang G.-C.; Hsia T.-C.; Hsu N.-Y.; Tsai Y.-H.; Tsai C.-M.; CHIH-HSIN YANG ; Chen Y.-M.; CHONG-JEN YU ; Lee J.-J.; Hsu H.-S.; Yu C.-T.; Kao E.-L.; Chiu C.-H. | Japanese Journal of Clinical Oncology | 12 | 7 | |
| 2020 | Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial | CHIH-HSIN YANG ; Camidge D.R.; Yang C.-T.; Zhou J.; Guo R.; Chiu C.-H.; Chang G.-C.; Shiah H.-S.; Chen Y.; Wang C.-C.; Berz D.; Su W.-C.; Yang N.; Wang Z.; Fang J.; Chen J.; Nikolinakos P.; Lu Y.; Pan H.; Maniam A.; Bazhenova L.; Shirai K.; Jahanzeb M.; Willis M.; Masood N.; Chowhan N.; Hsia T.-C.; Jian H.; Lu S. | Journal of Thoracic Oncology | 76 | 68 | |
